Precision Medicine Group (PMG), a US-based next-generation provider of drug development and commercialisation services, announced on Monday that it has named John Hubbard, PhD, as chairman of its board of directors.

Dr Hubbard has over 35 years of experience in the biopharmaceutical and pharma-tech services industries and clinical research organisations (CROs). He has served as the president and chief executive officer of Bioclinica, senior vice president and worldwide head of Development Operations at Pfizer, a member of the Portfolio Strategy and Investment Committee, chair of the Enterprise Precision Medicine Steering Committee, and member of the Worldwide Research and Development Executive Leadership Team and group president of ICON plc's Global Clinical Research Services Division. Presently, he serves on the boards of various life science companies, including Advarra, Signant Health, Agile Therapeutics, and Science 37.

Mark Clein, Precision Medicine Group chief executive officer, said: "We are thrilled to welcome John to our Board. He is a highly regarded leader in the pharmaceutical industry with extensive experience in clinical development and operations, strategic planning and business development. His impressive qualifications make him uniquely qualified to appreciate the breadth of services offered across our organization and to provide valuable insight as we continue to expand our global footprint and integrated capabilities."